

Olivier Tredan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/422150/publications.pdf>

Version: 2024-02-01

120
papers

8,506
citations

81900

39
h-index

46799

89
g-index

140
all docs

140
docs citations

140
times ranked

15351
citing authors

#	ARTICLE	IF	CITATIONS
1	Regorafenib or Tamoxifen for platinum-sensitive recurrent ovarian cancer with rising CA125 and no evidence of clinical or RECIST progression: A GINECO randomized phase II trial (REGOVAR). <i>Gynecologic Oncology</i> , 2022, 164, 18-26.	1.4	4
2	Molecular profile to guide personalized medicine in adult patients with primary brain tumors: results from the ProfILER trial. <i>Medical Oncology</i> , 2022, 39, 4.	2.5	3
3	Precision medicine for patients with gastro-oesophageal cancer: A subset analysis of the ProfILER program. <i>Translational Oncology</i> , 2022, 15, 101266.	3.7	3
4	Validation of the geriatric vulnerability score in older patients with ovarian cancer: an analysis from the GCIG-ENGOT-GINECO EWOC-1 study. <i>The Lancet Healthy Longevity</i> , 2022, 3, e176-e185.	4.6	4
5	A phase III randomized trial of weight loss to reduce cancer-related fatigue among overweight and obese breast cancer patients: MEDEA Study design. <i>Trials</i> , 2022, 23, 193.	1.6	9
6	Dynamics of Long-Term Patient-Reported Quality of Life and Health Behaviors After Adjuvant Breast Cancer Chemotherapy. <i>Journal of Clinical Oncology</i> , 2022, 40, 3190-3204.	1.6	23
7	Effects of an Exercise and Nutritional Intervention on Circulating Biomarkers and Metabolomic Profiling During Adjuvant Treatment for Localized Breast Cancer: Results From the PASAPAS Feasibility Randomized Controlled Trial. <i>Integrative Cancer Therapies</i> , 2021, 20, 153473542097766.	2.0	6
8	Analysis of genomic and non-genomic signaling of estrogen receptor in PDX models of breast cancer treated with a combination of the PI3K inhibitor alpelisib (BYL719) and fulvestrant. <i>Breast Cancer Research</i> , 2021, 23, 57.	5.0	7
9	Sarcopenia and serum biomarkers of oxidative stress after a 6-month physical activity intervention in women with metastatic breast cancer: results from the ABLE feasibility trial. <i>Breast Cancer Research and Treatment</i> , 2021, 188, 601-613.	2.5	16
10	Long-term patient reported outcomes and hematologic toxicity among patients who received Granulocyte-Colony Stimulating Factors during chemotherapy for early breast cancer. <i>Breast</i> , 2021, 57, 43-48.	2.2	2
11	Niraparib for Advanced Breast Cancer with Germline <i>BRCA1</i> and <i>BRCA2</i> Mutations: the EORTC 1307-BCG/BIG5-13/TESARO PR-30-50-10-C BRAVO Study. <i>Clinical Cancer Research</i> , 2021, 27, 5482-5491.	7.0	25
12	Impact of Physical Activity on Oxidative Stress Markers in Patients with Metastatic Breast Cancer. <i>Oxidative Medicine and Cellular Longevity</i> , 2021, 2021, 1-9.	4.0	9
13	Non-genomic signaling of steroid receptors in cancer. <i>Molecular and Cellular Endocrinology</i> , 2021, 538, 111453.	3.2	24
14	Targeting AKT in ER-Positive HER2-Negative Metastatic Breast Cancer: From Molecular Promises to Real Life Pitfalls?. <i>International Journal of Molecular Sciences</i> , 2021, 22, 13512.	4.1	6
15	Physical activity preferences before and after participation in a 6-month physical activity intervention among women with metastatic breast cancer. <i>European Journal of Cancer Care</i> , 2020, 29, e13169.	1.5	16
16	Impact of Breast Cancer Treatment on Employment: Results of a Multicenter Prospective Cohort Study (CANTO). <i>Journal of Clinical Oncology</i> , 2020, 38, 734-743.	1.6	69
17	Therapeutic relevance of molecular screening program in patients with metastatic sarcoma: Analysis from the ProfILER 01 trial. <i>Translational Oncology</i> , 2020, 13, 100870.	3.7	8
18	Serum Detection of Nonadherence to Adjuvant Tamoxifen and Breast Cancer Recurrence Risk. <i>Journal of Clinical Oncology</i> , 2020, 38, 2762-2772.	1.6	80

#	ARTICLE	IF	CITATIONS
19	High mortality rate in cancer patients with symptoms of COVID-19 with or without detectable SARS-COV-2 on RT-PCR. <i>European Journal of Cancer</i> , 2020, 135, 251-259.	2.8	102
20	Rapalog-Mediated Repression of Tribbles Pseudokinase 3 Regulates Pre-mRNA Splicing. <i>Cancer Research</i> , 2020, 80, 2190-2203.	0.9	4
21	Tumor Molecular Profiling: Pediatric Results of the ProFiLER Study. <i>JCO Precision Oncology</i> , 2020, 4, 785-795.	3.0	3
22	Design and methods of a national, multicenter, randomized and controlled trial to assess the efficacy of a physical activity program to improve health-related quality of life and reduce fatigue in women with metastatic breast cancer: ABLE02 trial. <i>BMC Cancer</i> , 2020, 20, 622.	2.6	5
23	Analysis of the StoRM cohort reveals physical activity to be associated with survival in metastatic breast cancer. <i>Scientific Reports</i> , 2020, 10, 10757.	3.3	8
24	IFN-III is selectively produced by cDC1 and predicts good clinical outcome in breast cancer. <i>Science Immunology</i> , 2020, 5, .	11.9	86
25	Feasibility and Health Benefits of an Individualized Physical Activity Intervention in Women With Metastatic Breast Cancer: Intervention Study. <i>JMIR MHealth and UHealth</i> , 2020, 8, e12306.	3.7	27
26	Actionable molecular alterations in advanced gynaecologic malignancies: updated results from the ProFiLER programme. <i>European Journal of Cancer</i> , 2019, 118, 156-165.	2.8	11
27	The arginine methyltransferase PRMT1 regulates IGF-1 signaling in breast cancer. <i>Oncogene</i> , 2019, 38, 4015-4027.	5.9	28
28	Feasibility of an exercise and nutritional intervention for weight management during adjuvant treatment for localized breast cancer: the PASAPAS randomized controlled trial. <i>Supportive Care in Cancer</i> , 2019, 27, 3449-3461.	2.2	20
29	Oestrogen Non-Genomic Signalling is Activated in Tamoxifen-Resistant Breast Cancer. <i>International Journal of Molecular Sciences</i> , 2019, 20, 2773.	4.1	13
30	UNICANCER: French prospective cohort study of treatment-related chronic toxicity in women with localised breast cancer (CANTO). <i>ESMO Open</i> , 2019, 4, e000562.	4.5	53
31	BRCA1/BRCA2 germline mutations and chemotherapy-related hematological toxicity in breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2019, 174, 775-783.	2.5	15
32	LKB1 regulates PRMT5 activity in breast cancer. <i>International Journal of Cancer</i> , 2019, 144, 595-606.	5.1	34
33	Phase I feasibility study for intrathecal administration of trastuzumab in patients with HER2 positive breast carcinomatous meningitis. <i>European Journal of Cancer</i> , 2018, 95, 75-84.	2.8	72
34	Autocrine Adenosine Regulates Tumor Polyfunctional CD73+CD4+ Effector T Cells Devoid of Immune Checkpoints. <i>Cancer Research</i> , 2018, 78, 3604-3618.	0.9	53
35	Location of Mutation in <i>BRCA2</i> Gene and Survival in Patients with Ovarian Cancer. <i>Clinical Cancer Research</i> , 2018, 24, 326-333.	7.0	40
36	Percutaneous cryoablation of breast tumours in patients with stable metastatic breast cancer: safety, feasibility and efficacy. <i>British Journal of Radiology</i> , 2018, 91, 20170500.	2.2	17

#	ARTICLE	IF	CITATIONS
37	Exploitation of Precision Medicine Trials Data: Examples of Long Responders From the SHIVA01 Trial. <i>JCO Precision Oncology</i> , 2018, 2, 1-11.	3.0	0
38	A Personalized Physical Activity Program With Activity Trackers and a Mobile Phone App for Patients With Metastatic Breast Cancer: Protocol for a Single-Arm Feasibility Trial. <i>JMIR Research Protocols</i> , 2018, 7, e10487.	1.0	18
39	Soluble VE-cadherin in metastatic breast cancer: an independent prognostic factor for both progression-free survival and overall survival. <i>British Journal of Cancer</i> , 2017, 116, 356-361.	6.4	19
40	Randomized phase II trial comparing molecularly targeted therapy based on tumor molecular profiling versus conventional therapy in patients with refractory cancer: cross-over analysis from the SHIVA trial. <i>Annals of Oncology</i> , 2017, 28, 590-596.	1.2	58
41	A randomized phase II trial of ridaforolimus, dalotuzumab, and exemestane compared with ridaforolimus and exemestane in patients with advanced breast cancer. <i>Breast Cancer Research and Treatment</i> , 2017, 165, 601-609.	2.5	25
42	MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer. <i>Journal of Clinical Oncology</i> , 2017, 35, 3638-3646.	1.6	1,099
43	Longitudinal serum metabolomics evaluation of trastuzumab and everolimus combination as pre-operative treatment for HER-2 positive breast cancer patients. <i>Oncotarget</i> , 2017, 8, 83570-83584.	1.8	18
44	A Systematic Evaluation of Blood Serum and Plasma Pre-Analytics for Metabolomics Cohort Studies. <i>International Journal of Molecular Sciences</i> , 2016, 17, 2035.	4.1	56
45	A phase II trial of abiraterone acetate plus prednisone in patients with triple-negative androgen receptor positive locally advanced or metastatic breast cancer (UCBG 12-1). <i>Annals of Oncology</i> , 2016, 27, 812-818.	1.2	234
46	PI3K targeting in breast cancer: the end of the beginning?. <i>Lancet Oncology</i> , The, 2016, 17, 696-697.	10.7	1
47	Safety of bevacizumab in clinical practice for recurrent ovarian cancer: A retrospective cohort study. <i>Oncology Letters</i> , 2016, 11, 1859-1865.	1.8	8
48	A whole-genome sequence and transcriptome perspective on HER2-positive breast cancers. <i>Nature Communications</i> , 2016, 7, 12222.	12.8	113
49	Immune cell dysfunctions in breast cancer patients detected through whole blood multi-parametric flow cytometry assay. <i>Oncolimmunology</i> , 2016, 5, e1100791.	4.6	66
50	Pegfilgrastim Enhances the Antitumor Effect of Therapeutic Monoclonal Antibodies. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 1238-1247.	4.1	11
51	A phase III trial of exemestane plus bevacizumab maintenance therapy in patients with metastatic breast cancer after first-line taxane and bevacizumab: a GINECO group study. <i>Annals of Oncology</i> , 2016, 27, 1020-1029.	1.2	25
52	SHIVA: Randomized phase II trial comparing molecularly targeted therapy based on tumor molecular profiling versus conventional therapy in patients with refractory cancerâ€™PFS ratio from patients who crossed-over.. <i>Journal of Clinical Oncology</i> , 2016, 34, 2535-2535.	1.6	1
53	Management of Antiangiogenic Agents. , 2016, , 69-77.		1
54	Deterioration of Physical Activity Level and Metabolic Risk Factors After Early-Stage Breast Cancer Diagnosis. <i>Cancer Nursing</i> , 2015, 38, E1-E9.	1.5	25

#	ARTICLE	IF	CITATIONS
55	Role of JMJD6 in Breast Tumourigenesis. PLoS ONE, 2015, 10, e0126181.	2.5	48
56	Prevalence of depressive syndrome in patients with breast cancer treated with or without aromatase inhibitors. Oncologie, 2015, 17, 587-594.	0.7	1
57	Ixabepilone Alone or With Cetuximab as First-Line Treatment for Advanced/Metastatic Triple-Negative Breast Cancer. Clinical Breast Cancer, 2015, 15, 8-15.	2.4	47
58	Neoadjuvant treatment with docetaxel plus lapatinib, trastuzumab, or both followed by an anthracycline-based chemotherapy in HER2-positive breast cancer: results of the randomised phase II EORTC 10054 study. Annals of Oncology, 2015, 26, 325-332.	1.2	67
59	Survivorship in untreated breast cancer patients. Medical Oncology, 2015, 32, 466.	2.5	6
60	ELYPSE-7: a randomized placebo-controlled phase IIa trial with CYT107 exploring the restoration of CD4+ lymphocyte count in lymphopenic metastatic breast cancer patients. Annals of Oncology, 2015, 26, 1353-1362.	1.2	63
61	Therogenetics: transferring GWAS technology to the clinic. Mutagenesis, 2015, 30, 213-215.	2.6	1
62	A serum metabolomic fingerprint of bevacizumab and temsirolimus combination as first-line treatment of metastatic renal cell carcinoma. British Journal of Cancer, 2015, 113, 1148-1157.	6.4	20
63	Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial. Lancet Oncology, The, 2015, 16, 1324-1334.	10.7	897
64	Angiogenesis and tumor microenvironment: bevacizumab in the breast cancer model. Targeted Oncology, 2015, 10, 189-198.	3.6	33
65	Abstract P5-19-17: Final results of the phase I "HIT" study: A multicenter phase I-II study evaluating trastuzumab administered by intrathecal injection for leptomeningeal meningitis of HER2+ metastatic breast cancer (MBC)., 2015, , .		3
66	Abstract PD5-1: Results from the phase 2 trial of ridaforolimus, dalotuzumab, and exemestane compared to ridaforolimus and exemestane in advanced breast cancer. Cancer Research, 2015, 75, PD5-1-PD5-1.	0.9	7
67	Genomic alterations to predict response to irinotecan-based chemotherapy in metastatic colorectal cancer.. Journal of Clinical Oncology, 2015, 33, 586-586.	1.6	2
68	The sum of gains and losses of genes encoding the protein tyrosine kinase targets predicts response to multi-kinase inhibitor treatment: Characterization, validation, and prognostic value. Oncotarget, 2015, 6, 26388-26399.	1.8	9
69	A serum nuclear magnetic resonance-based metabolomic signature of advanced metastatic human breast cancer. Cancer Letters, 2014, 343, 33-41.	7.2	133
70	Concomitant resistance and early-breast cancer: should we change treatment strategies?. Cancer and Metastasis Reviews, 2014, 33, 271-283.	5.9	11
71	Trends in cancer-targeted antibody-drug conjugates. Targeted Oncology, 2014, 9, 1-8.	3.6	7
72	Multicentric neoadjuvant phase II study of panitumumab combined with an anthracycline/taxane-based chemotherapy in operable triple-negative breast cancer: identification of biologically defined signatures predicting treatment impact. Annals of Oncology, 2014, 25, 1570-1577.	1.2	90

#	ARTICLE	IF	CITATIONS
73	Catumaxomab with and without prednisolone premedication for the treatment of malignant ascites due to epithelial cancer: results of the randomised phase IIIb CASIMAS study. <i>Medical Oncology</i> , 2014, 31, 76.	2.5	13
74	Randomised proof-of-concept phase II trial comparing targeted therapy based on tumour molecular profiling vs conventional therapy in patients with refractory cancer: results of the feasibility part of the SHIVA trial. <i>British Journal of Cancer</i> , 2014, 111, 17-24.	6.4	70
75	Identifying actionable targets in advanced cancer patients: Preliminary results from the Profiler program.. <i>Journal of Clinical Oncology</i> , 2014, 32, 2621-2621.	1.6	1
76	Arobase: A phase III trial of exemestane (Exe) and bevacizumab (BEV) as maintenance therapy in patients (pts) with metastatic breast cancer (MBC) treated in first line with paclitaxel (P) and BEV. <i>A Gineco study.. Journal of Clinical Oncology</i> , 2014, 32, 501-501.	1.6	3
77	Independent review of AGO-OVAR 12, a GCIG/ENGOT-Intergroup phase III trial of nintedanib (N) in first-line therapy for ovarian cancer (OC).. <i>Journal of Clinical Oncology</i> , 2014, 32, 5556-5556.	1.6	2
78	Efficacy and toxicity profile of eribulin mesylate for metastatic breast cancer (MBC) patients (pts) in the routine clinic: A French observational study.. <i>Journal of Clinical Oncology</i> , 2014, 32, e11555-e11555.	1.6	0
79	ELYPSE-7: A randomized, placebo-controlled, phase 2a study evaluating the impact of IL-7 on CD4 count, hematological toxicity, and tumor progression in metastatic breast cancer (MBC) patients (pts).. <i>Journal of Clinical Oncology</i> , 2014, 32, 3033-3033.	1.6	1
80	Abstract 2574: Interleukin-7 (CYT107) treatment in lymphopenic 1st line metastatic breast carcinoma patients treated with chemotherapy regimen (Capecitabine) favors the restoration of T-cell subsets number. , 2014, , .		0
81	Abstract CT333: Elypse-7: A randomized, placebo-controlled, Phase 2a evaluating the impact of IL-7 immunotherapy on CD4 count, risks of severe haematological toxicity and tumor progression in metastatic breast cancer patients. , 2014, , .		0
82	Abstract LB-253: A comprehensive evaluation of immune checkpoints ligands (ICPLs) in more than 1,000 cancer cell lines (CCLs) identifies specific expression patterns. , 2014, , .		0
83	Targeted treatments for breast cancer: a step forward. <i>Lancet Oncology</i> , The, 2013, 14, 438-439.	10.7	3
84	Patients with metastatic breast cancer leading to CD4+ T cell lymphopaenia have poor outcome. <i>European Journal of Cancer</i> , 2013, 49, 1673-1682.	2.8	42
85	CD4 lymphopenia to identify end-of-life metastatic cancer patients. <i>European Journal of Cancer</i> , 2013, 49, 1080-1089.	2.8	31
86	Distribution of the anticancer drugs doxorubicin, mitoxantrone and topotecan in tumors and normal tissues. <i>Cancer Chemotherapy and Pharmacology</i> , 2013, 72, 127-138.	2.3	63
87	Predicting everolimus treatment efficacy in patients with advanced endometrial carcinoma: a GINECO group study. <i>Targeted Oncology</i> , 2013, 8, 243-251.	3.6	44
88	Design of a randomised controlled trial of adapted physical activity during adjuvant treatment for localised breast cancer: the PASAPAS feasibility study. <i>BMJ Open</i> , 2013, 3, e003855.	1.9	10
89	Development of a geriatric vulnerability score in elderly patients with advanced ovarian cancer treated with first-line carboplatin: a GINECO prospective trial. <i>Annals of Oncology</i> , 2013, 24, 2808-2813.	1.2	97
90	Primary Ovarian Borderline Tumor in the Inguinal Lymph Node. <i>International Journal of Gynecological Pathology</i> , 2013, 32, 167-170.	1.4	5

#	ARTICLE	IF	CITATIONS
91	Obesity and survival in operable breast cancer patients treated with adjuvant anthracyclines and taxanes according to pathological subtypes: a pooled analysis. <i>Breast Cancer Research</i> , 2013, 15, R105.	5.0	80
92	Abstract LB-171: Randomized phase II trial comparing therapy based on tumor molecular profiling versus conventional therapy in patients with refractory cancer: Preliminary results of the feasibility of the SHIVA trial. , 2013, , .		0
93	Depression assessment by oncologists and palliative care physicians. <i>Palliative and Supportive Care</i> , 2012, 10, 255-263.	1.0	10
94	Mechanisms of resistance to endocrine therapies for breast cancer. <i>Hormone Molecular Biology and Clinical Investigation</i> , 2012, 9, 165-171.	0.7	0
95	Lymphopenia combined with low TCR diversity (divpenia) predicts poor overall survival in metastatic breast cancer patients. <i>Oncolmmunology</i> , 2012, 1, 432-440.	4.6	102
96	Designs and challenges for personalized medicine studies in oncology: focus on the SHIVA trial. <i>Targeted Oncology</i> , 2012, 7, 253-265.	3.6	57
97	Activation of rapid oestrogen signalling in aggressive human breast cancers. <i>EMBO Molecular Medicine</i> , 2012, 4, 1200-1213.	6.9	55
98	Frequency of depression among oncology outpatients and association with other symptoms. <i>Supportive Care in Cancer</i> , 2012, 20, 2795-2802.	2.2	41
99	Gene expression profiling identifies sST2 as an effector of ErbB2-driven breast carcinoma cell motility, associated with metastasis. <i>Oncogene</i> , 2012, 31, 3516-3524.	5.9	30
100	First-line endocrine therapy alone could be a reasonable treatment option for hormone-positive, HER2-positive metastatic breast cancer. <i>Bulletin Du Cancer</i> , 2012, 99, E18-E25.	1.6	3
101	Quantitative and Functional Alterations of Plasmacytoid Dendritic Cells Contribute to Immune Tolerance in Ovarian Cancer. <i>Cancer Research</i> , 2011, 71, 5423-5434.	0.9	200
102	The ribonucleotide reductase large subunit (RRM1) as a predictive factor in patients with cancer. <i>Lancet Oncology</i> , The, 2011, 12, 693-702.	10.7	147
103	Bevacizumab plus microtubule targeting agents in heavily pre-treated ovarian cancer patients: a retrospective study. <i>Bulletin Du Cancer</i> , 2011, 98, E80-E89.	1.6	6
104	Chemotherapy for metastatic breast cancer. Comparison of clinical practice and cost of drugs in two cohorts of patients: 1994â€“1998 and 2003â€“2006. <i>Breast Cancer Research and Treatment</i> , 2011, 128, 187-195. ^{2.5}		10
105	Prognostic value of the expression of C-Chemokine Receptor 6 and 7 and their ligands in non-metastatic breast cancer. <i>BMC Cancer</i> , 2011, 11, 213.	2.6	31
106	Validation of prognostic scores for survival in cancer patients beyond first-line therapy. <i>BMC Cancer</i> , 2011, 11, 95.	2.6	33
107	Abstract LB-165: Low TCR diversity (divpenia) is a new prognosis factor of overall survival in metastatic breast cancer. , 2011, , .		0
108	Abstract 2267: Long term prognostic impact of CD4 and CD8 lymphopenia and rapid recovery in a cohort of 220 patients with a 10 years follow-up. , 2011, , .		0

#	ARTICLE	IF	CITATIONS
109	La mÃ©tabolomique: un nouvel outil pour la recherche translationnelle en cancérologie. <i>Oncologie</i> , 2010, 12, 409-415.	0.7	0
110	Factors of interrupting chemotherapy in patients with Advanced Non-Small-Cell Lung Cancer. <i>BMC Research Notes</i> , 2010, 3, 164.	1.4	7
111	Body weight change in women receiving adjuvant chemotherapy for breast cancer: A French prospective study. <i>Clinical Nutrition</i> , 2010, 29, 187-191.	5.0	65
112	Phase II of oral gimatecan in patients with recurrent epithelial ovarian, fallopian tube or peritoneal cancer, previously treated with platinum and taxanes. <i>Annals of Oncology</i> , 2010, 21, 759-765.	1.2	25
113	Hyperthermic intraperitoneal chemotherapy with oxaliplatin and without adjuvant chemotherapy in stage IIIc ovarian cancer. <i>Bulletin Du Cancer</i> , 2010, 97, E23-E32.	1.6	21
114	The Hypoxia-Activated ProDrug AQ4N Penetrates Deeply in Tumor Tissues and Complements the Limited Distribution of Mitoxantrone. <i>Cancer Research</i> , 2009, 69, 940-947.	0.9	47
115	Lymphopenia as a Prognostic Factor for Overall Survival in Advanced Carcinomas, Sarcomas, and Lymphomas. <i>Cancer Research</i> , 2009, 69, 5383-5391.	0.9	610
116	Carboplatin/cyclophosphamide or carboplatin/paclitaxel in elderly patients with advanced ovarian cancer? Analysis of two consecutive trials from the Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens. <i>Annals of Oncology</i> , 2007, 18, 256-262.	1.2	76
117	Drug Resistance and the Solid Tumor Microenvironment. <i>Journal of the National Cancer Institute</i> , 2007, 99, 1441-1454.	6.3	1,795
118	Expression of Class III β -Tubulin Is Predictive of Patient Outcome in Patients with Non-Small Cell Lung Cancer Receiving Vinorelbine-Based Chemotherapy. <i>Clinical Cancer Research</i> , 2005, 11, 5481-5486.	7.0	193
119	Class III β -tubulin expression in tumor cells predicts response and outcome in patients with non-small cell lung cancer receiving paclitaxel. <i>Molecular Cancer Therapeutics</i> , 2005, 4, 2001-2007.	4.1	224
120	cN-II expression predicts survival in patients receiving gemcitabine for advanced non-small cell lung cancer. <i>Lung Cancer</i> , 2005, 49, 363-370.	2.0	62